Capstone Asset Management Co. Buys New Position in Alnylam Pharmaceuticals, Inc. (ALNY)
Capstone Asset Management Co. bought a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 2,909 shares of the biopharmaceutical company’s stock, valued at approximately $232,000.
Several other hedge funds have also recently made changes to their positions in ALNY. Dimensional Fund Advisors LP increased its stake in shares of Alnylam Pharmaceuticals by 0.6% in the fourth quarter. Dimensional Fund Advisors LP now owns 111,350 shares of the biopharmaceutical company’s stock valued at $4,170,000 after buying an additional 695 shares in the last quarter. Teachers Advisors LLC increased its stake in shares of Alnylam Pharmaceuticals by 10.6% in the fourth quarter. Teachers Advisors LLC now owns 73,576 shares of the biopharmaceutical company’s stock valued at $2,755,000 after buying an additional 7,048 shares in the last quarter. Macquarie Group Ltd. increased its stake in shares of Alnylam Pharmaceuticals by 10.0% in the fourth quarter. Macquarie Group Ltd. now owns 17,755 shares of the biopharmaceutical company’s stock valued at $665,000 after buying an additional 1,614 shares in the last quarter. Bank of Montreal Can increased its stake in shares of Alnylam Pharmaceuticals by 283.6% in the first quarter. Bank of Montreal Can now owns 9,528 shares of the biopharmaceutical company’s stock valued at $488,000 after buying an additional 7,044 shares in the last quarter. Finally, Nisa Investment Advisors LLC purchased a new stake in shares of Alnylam Pharmaceuticals during the first quarter valued at approximately $256,000. Institutional investors own 88.99% of the company’s stock.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ ALNY) traded up 1.42% during trading on Friday, reaching $81.42. 574,759 shares of the company’s stock were exchanged. The firm’s market cap is $7.47 billion. Alnylam Pharmaceuticals, Inc. has a 12 month low of $31.38 and a 12 month high of $86.92. The stock has a 50-day moving average price of $80.83 and a 200 day moving average price of $63.46.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by $0.12. Alnylam Pharmaceuticals had a negative net margin of 670.81% and a negative return on equity of 45.53%. The business had revenue of $15.93 million for the quarter, compared to analysts’ expectations of $23.86 million. During the same period in the previous year, the company earned ($1.05) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 82.9% compared to the same quarter last year. On average, analysts forecast that Alnylam Pharmaceuticals, Inc. will post ($5.21) EPS for the current year.
COPYRIGHT VIOLATION NOTICE: This article was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.dailypolitical.com/2017/08/19/capstone-asset-management-co-buys-new-position-in-alnylam-pharmaceuticals-inc-alny.html.
Several analysts have recently commented on ALNY shares. Chardan Capital set a $95.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Friday, May 5th. Morgan Stanley increased their target price on shares of Alnylam Pharmaceuticals from $39.00 to $42.00 and gave the company an “equal weight” rating in a report on Monday, May 8th. Credit Suisse Group reiterated a “hold” rating and issued a $50.00 target price on shares of Alnylam Pharmaceuticals in a report on Tuesday, May 9th. Piper Jaffray Companies set a $118.00 target price on shares of Alnylam Pharmaceuticals and gave the company a “buy” rating in a report on Monday, May 15th. Finally, Vetr downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 target price for the company. in a report on Monday, May 15th. One analyst has rated the stock with a sell rating, eight have issued a hold rating and fourteen have given a buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $81.74.
In related news, EVP Akshay Vaishnaw sold 11,000 shares of the stock in a transaction that occurred on Tuesday, May 23rd. The shares were sold at an average price of $75.00, for a total value of $825,000.00. Following the completion of the sale, the executive vice president now directly owns 21,297 shares of the company’s stock, valued at approximately $1,597,275. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Sanofi bought 297,501 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Wednesday, May 31st. The stock was purchased at an average cost of $71.87 per share, with a total value of $21,381,396.87. The disclosure for this purchase can be found here. 4.30% of the stock is owned by corporate insiders.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.